New Research: Europe Multiparameter Patient Monitoring Devices Market

Latest industry research report on: Europe Multiparameter Patient Monitoring Devices Market | Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts

GBI Research’s report, ""Market Digest: Multiparameter Patient Monitoring Devices 2006 to 2020 Europe (Germany, France, Italy, UK and Spain)” provides quantitative analysis of the four multiparameter patient monitoring devices market segments: high acuity monitors, mid acuity monitors, low acuity monitors and multiparameter central stations. The analysis includes market size data by revenue and volume over the 2006–2020 period for the following countries: Germany, France, UK, Italy and Spain. It uses data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

Scope

• Information on market size for the four multiparameter patient monitoring devices market segments: high acuity monitors, mid acuity monitors, low acuity monitors and multiparameter central stations
• Annualized sales data by revenue for the 2006–2020 period and company share data by revenue for 2013
• Annualized sales data by volume for the 2006–2020 period
• Coverage of key geographies: Germany, France, UK, Italy and Spain

Download Sample copy of this Report at :http://www.marketresearchreports.biz/sample/sample/237222

Reasons to buy

• Derive actionable insights from value-volume relationships
• Analyze value-volume relationships and provide direction to marketing and sales strategies
• Develop market-entry and market-expansion strategies
• Identify the key players best positioned to take advantage of opportunities in the European market

Table of Contents

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 4

1.2 List of Figures 6

2 GBI Research Report Guidance 8

3 Definitions 8

3.1 Multiparameter Patient Monitoring Devices 8

3.2 High Acuity Monitors 8

3.2.1 Critical Care Monitors 8

3.2.2 MRI Compatible Monitors 8

3.2.3 Perioperative Care Monitors 8

3.3 Mid Acuity Monitors 8

3.3.1 Emergency Care Monitors 8

3.3.2 Post Anesthesia Care Monitors 8

3.4 Low Acuity Monitors 8

3.4.1 Ambulatory Monitors 8

3.4.2 Vital Signs Monitors 8

3.5 Central Stations 8

4 Multiparameter Patient Monitoring Devices Market, Europe, Revenue, 2006–2020 9

4.1 Multiparameter Patient Monitoring Devices Market, Europe, Revenue ($m), 2006–2013 9

4.2 Multiparameter Patient Monitoring Devices Market, Europe, Revenue ($m), 2013–2020 9

5 Multiparameter Patient Monitoring Devices Market, Germany, Revenue and Volume, 2006–2020 11

5.1 Multiparameter Patient Monitoring Devices Market, Germany, Revenue ($m), 2006–2013 11

5.2 Multiparameter Patient Monitoring Devices Market, Germany, Revenue ($m), 2013–2020 11

5.3 High Acuity Monitors Market, Germany 12

5.3.1 High Acuity Monitors Market, Germany, Revenue ($m), 2006–2013 12

5.3.2 High Acuity Monitors Market, Germany, Revenue ($m), 2013–2020 12

5.3.3 High Acuity Monitors Market, Germany, Volume (‘000), 2006–2013 13

5.3.4 High Acuity Monitors Market, Germany, Volume (‘000), 2013–2020 13

5.4 Mid Acuity Monitors Market, Germany 14

5.4.1 Mid Acuity Monitors Market, Germany, Revenue ($m), 2006–2013 14

5.4.2 Mid Acuity Monitors Market, Germany, Revenue ($m), 2013–2020 14

5.4.3 Mid Acuity Monitors Market, Germany, Volume (‘000), 2006–2013 15

5.4.4 Mid Acuity Monitors Market, Germany, Volume (‘000), 2013–2020 15

5.5 Low Acuity Monitors Market, Germany 16

5.5.1 Low Acuity Monitors Market, Germany, Revenue ($m), 2006–2013 16

5.5.2 Low Acuity Monitors Market, Germany, Revenue ($m), 2013–2020 16

5.5.3 Low Acuity Monitors Market, Germany, Volume (‘000), 2006–2013 17

5.5.4 Low Acuity Monitors Market, Germany, Volume (‘000), 2013–2020 17

5.6 Central Stations Market, Germany 18

About us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact

Mr. Nachiket

State Tower

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-621-2074

Website: http://www.marketresearchreports.biz/

E: sales@marketresearchreports.biz

Recent Release: Europe Aesthetic Lasers and Energy Devices Market

Latest industry research report on: Aesthetic Lasers and Energy Devices Market : Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts

The report covers the Europe (Germany, France, Italy, UK and Spain) aesthetic lasers and energy devices market revenue and volume for the following segments: Minimally Invasive Body Contouring (MIBC) Devices, Non-Invasive Body Contouring (NIBC) Devices and Laser Resurfacing (LR) Devices. The report also provides company shares by revenue for the above mentioned countries for the year 2013.

Scope

• Information on market size for the three aesthetic lasers and energy devices market segments: minimally invasive body contouring devices, non-invasive body contouring devices and laser resurfacing devices.
• Annualized sales data by revenue for the 2006–2020 period and company share data by revenue for 2013
• Annualized sales data by volume for the 2006–2020 period
• Coverage of key geographies: Germany, France, Italy, UK and Spain

Download Sample copy of this Report at :http://www.marketresearchreports.biz/sample/sample/242890

Reasons to buy

• Derive actionable insights from value-volume relationships
• Analyze value-volume relationships and provide direction to marketing and sales strategies
• Develop market-entry and market-expansion strategies
• Identify the key players best positioned to take advantage of opportunities in the European market

Table of Contents

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 4

1.2 List of Figures 5

2 GBI Research Report Guidance 7

3 Definitions 7

3.1 Minimally Invasive Body Contouring Devices 7

3.1.1 Laser Assisted Liposuction Devices 7

3.1.2 Radio Frequency Assisted Liposuction Devices 7

3.1.3 Ultrasound Assisted Liposuction Devices 7

3.1.4 Power Assisted Liposuction Devices 7

3.2 Non-Invasive Body Contouring Devices 7

3.2.1 High Intensity Focused Ultrasound Devices 7

3.2.2 Radio Frequency Energy Devices 7

3.3 Laser Resurfacing Devices 7

3.3.1 CO2 Laser Devices 7

3.3.2 Er:YAG Laser Devices 7

3.3.3 Q-Switched Laser Devices 7

4 Aesthetic Lasers and Energy Devices Market, Europe, Revenue, 2006–2020 8

4.1 Aesthetic Lasers and Energy Devices Market, Europe, Revenue ($m), 2006–2013 8

4.2 Aesthetic Lasers and Energy Devices Market, Europe, Revenue ($m), 2013–2020 8

5 Aesthetic Lasers and Energy Devices Market, Germany, Revenue and Volume, 2006–2020 10

5.1 Aesthetic Lasers and Energy Devices Market, Germany, Revenue ($m), 2006–2013 10

5.2 Aesthetic Lasers and Energy Devices Market, Germany, Revenue ($m), 2013–2020 10

5.3 Minimally Invasive Body Contouring Devices Market , Germany 11

5.3.1 Minimally Invasive Body Contouring Devices Market, Germany, Revenue ($m), 2006–2013 11

5.3.2 Minimally Invasive Body Contouring Devices Market, Germany, Revenue ($m), 2013–2020 11

5.3.3 Minimally Invasive Body Contouring Devices Market, Germany, Volume (Units), 2006–2013 12

5.3.4 Minimally Invasive Body Contouring Devices Market, Germany, Volume (Units), 2013–2020 12

5.4 Non-Invasive Body Contouring Devices Market, Germany 13

5.4.1 Non-Invasive Body Contouring Devices Market, Germany, Revenue ($m), 2006–2013 13

5.4.2 Non-Invasive Body Contouring Devices Market, Germany, Revenue ($m), 2013–2020 13

5.4.3 Non-Invasive Body Contouring Devices Market, Germany, Volume (Units), 2006-2013 14

5.4.4 Non-Invasive Body Contouring Devices Market, Germany, Volume (Units), 2013-2020 14

5.5 Laser Resurfacing Devices Market, Germany 15

About us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact

Mr. Nachiket

State Tower

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-621-2074

Website: http://www.marketresearchreports.biz/

E: sales@marketresearchreports.biz

New Released Report: Insulin Delivery Devices Market to 2019

Latest industry research report on: Insulin Delivery Devices Market | Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts

GBI Research’s report: Insulin Delivery Devices Market to 2019 examines the market, competitive landscape, and trends for the four insulin delivery devices market segments: insulin pens, insulin pumps, insulin syringes and traditional insulin pump accessories. It provides comprehensive information on the key trends affecting these segments, and key analytical content on the market dynamics. The report also reviews the competitive landscape, analyzes each segment’s pipeline products and gives details of important mergers and acquisitions. It is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

Download Sample copy of this Report at :http://www.marketresearchreports.biz/sample/sample/192953

Scope

• The markets of 12 key geographies are covered: US, Canada, UK, Germany, France, Italy, Spain, Japan, China, India, Australia and Brazil.
• Information on market size for the four insulin delivery devices market segments: insulin pens, insulin pumps, insulin syringes and traditional insulin pump accessories.
• Annual market revenue data forecast to 2019 and company share data for 2012.
• Qualitative analysis of key trends in the insulin delivery devices market.
• Information on the competitive landscape and the leading technologies of key players: Novo Nordisk, Medtronic, Sanofi, Eli Lilly, Becton, Dickinson and Company, Animas, Insulet, F. Hoffmann-La Roche, Abbott Laboratories.
• Information on reimbursement trends and market access for key countries.

Reasons to Buy

• Develop business strategies by understanding the trends and developments driving the global insulin delivery devices market.
• Design and enhance your product development, marketing, and sales strategies.
• Exploit merger and acquisition opportunities by identifying the market players with the most innovative pipelines.
• Develop market-entry and market-expansion strategies.
• Identify the key players best positioned to take advantage of the emerging market opportunities.
• Exploit in-licensing and out-licensing opportunities by identifying the products most likely to ensure a robust return.
• Identify, understand and capitalize on the next big thing in the insulin delivery devices market landscape.
• Make more informed business decisions from insightful and in-depth analysis of the global insulin delivery devices market and the factors shaping it.

Table of Contents

1 Table of Contents 2

1.1 List of Tables 9

1.2 List of Figures 12

2 Executive Summary 14

2.1 Global Insulin Delivery Devices Market to see Significant Growth during the Forecast Period 14

2.2 New Entrants Act as Catalysts in Transformation from a Physician-Driven to Consumer-Driven Market 15

2.3 Large Players’ Market Shares Decline as New Entrants Introduce Consumer-Friendly Features in the US 16

2.4 Increasing Prevalence of Diabetes to Continue to Drive Growth in the Insulin Delivery Devices Market 18

2.5 Insulin Pumps Drive Growth in Developed Economies as Insulin Pens Drive Adoption in Emerging Economies 19

2.6 Collaborations Foster Innovation to Address Unmet Need in Artificial Pancreas Systems 21

2.7 Public Funding of Insulin Pumps will Provide Long-Term Economic Benefits 22

3 Introduction 23

3.1 GBI Research Report Guidance 24

4 Diabetes – Disease Overview 25

4.1 Types of Diabetes 25

4.1.1 Type 1 Diabetes 25

4.1.2 Type 2 Diabetes 25

4.1.3 Gestational Diabetes 25

4.1.4 Signs and Symptoms 26

4.1.5 Diabetes Diagnosis 26

5 Diabetes – Epidemiology 28

6 Global Insulin Delivery Devices Market: Device Overview 29

6.1 Insulin Pen 29

6.1.1 Reusable Pen 29

6.1.2 Disposable Pen 29

6.1.3 Pen Needle 30

6.2 Insulin Pump 30

6.2.1 Traditional Insulin Pump 30

6.2.2 Disposable Insulin Pump 30

6.3 Insulin Syringe 30

6.4 Traditional Insulin Pump Accessories 30

6.5 Comparison of Insulin Delivery Devices 31

About us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact

Mr. Nachiket

State Tower

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-621-2074

Website: http://www.marketresearchreports.biz/

E: sales@marketresearchreports.biz

Global HIV Therapeutics Market Will Reach At USD16.3 bn till year 2019

Latest industry research report on: Global HIV Therapeutics Market : Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts

The leading business intelligence provider GBI Research has released its latest research report, entitled “HIV Therapeutics Market to 2019 – Limited Pipeline Efficacy Improvement, Patent Expirations and Stringent Healthcare Spending to Suppress Market Growth”. The report provides insights into the HIV (Human Immunodeficiency Virus) therapeutics market including market forecasts up to 2019. It provides an in-depth analysis of the major marketed products, as well as insights into the HIV therapeutics R&D pipeline. The report provides in-depth analysis of the unmet needs, drivers and barriers that affect the global HIV therapeutics market. The report analyzes the market for HIV therapeutics in eight major markets of the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain), Japan and Canada.

The report discusses the global pipeline for all the HIV molecules across various stages of development. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts. GBI Research found that the HIV therapeutics market in the top seven markets was valued at $14.3 billion in 2012 and is projected to witness growth of 1.9% during the 2012–2019 forecast period to reach $16.3 billion.

Download Sample copy of this Report at :http://www.marketresearchreports.biz/sample/sample/195271

Scope

• The report analyzes treatment usage patterns, drug types available and pipeline and market forecasts across indications for HIV.
• The report covers and includes:
• A brief introduction to HIV, including the symptoms, pathogenesis, risk factors and diagnosis
• In-depth analysis of major glucose-lowering drugs for HIV, including analyses of their safety, efficacy, treatment patterns, strengths/weaknesses and overall commercial prospects. Includes a heat map comparing major drugs in terms of safety, efficacy and dosing parameters.
• Comprehensive review of the pipeline for HIV therapies, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market in the forecast period. The pipeline is analyzed on the basis of phase distribution, molecule types and molecular targets.
• Additional in-depth analysis of pipeline drug clinical trials by phase, molecule type, trial size, trial duration and program failure rate analyses for each molecule type and mechanism of action
• Multi-scenario forecast data for the market up to 2019, taking into account how it will be affected by the introduction of new drugs, the expiry of key patents on current drugs, and changes in disease epidemiology across key developed markets including the US, Japan, Germany, the UK, France, Italy, Spain and Canada
• Discussion of the drivers and barriers for market growth

Reasons to Buy

• The report will enhance your decision-making capability. It will allow you to:
• Align your product portfolio to the markets with high growth potential.
• Develop market-entry and market expansion strategies by identifying the potential region and HIV/AIDS therapeutics market segments poised for strong growth.
• Create a more tailored country strategy through the understanding of key drivers and barriers of the global HIV/AIDS therapeutics market.
• Develop key strategic initiatives by understanding the key focus areas and top selling products of leading companies.
• Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships.

About us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact

Mr. Nachiket

State Tower

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-621-2074

Website: http://www.marketresearchreports.biz/

E: sales@marketresearchreports.biz

Global Breast Cancer Market Size, Industry Analysis, Innovation, Overview, Growth Rate, Share and Forecasts

Latest industry research report on: Global Breast Cancer Market | Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts

The breast cancer pipeline is the largest in the pharmaceutical industry, with 1,050 products in active development across all stages. The range of mechanisms of action employed by these compounds is also highly diverse, especially in comparison to the existing market landscape. The degree and proportion of breakthrough innovations in this pipeline is exceptional & GBI Research analysis identified 333 first-in-class programs in the breast cancer pipeline, acting on 251 first-in-class molecular targets. This accounts for some 39% of all products with a disclosed molecular target, and is reflective of the high degree of innovation in this indication. This has far-reaching strategic implications for all market participants, as despite the high attrition rate in breast cancer, it is highly likely many of the first-in-class products will reach the market over the coming decade and, will have the opportunity to transform the clinical and commercial landscape.

Potential driving factors behind this market include a very large and growing patient pool, a well-established disease market with a number of strong unmet needs, and the strong understanding of the disease pathophysiology that has developed over the last decade, facilitating the development of novel compounds that may fill the unmet needs.

Some 289 first-in-class products that are currently in development have not yet been involved in licensing or co-development deals, meaning there are numerous opportunities for in-licensing or co-development in this indication, which already has a strong track record of breakthrough innovation yielding highly commercially and clinically successful therapies.

Download Sample copy of this Report at : http://www.marketresearchreports.biz/sample/sample/668359

Scope

• The report analyzes innovation in breast cancer, in the context of the overall pipeline and current market landscape. In addition, it analyzes the deals landscape surrounding first-in-class products in breast cancer, and pinpoints opportunities for in-licensing.
• A brief introduction to breast cancer, including symptoms, pathophysiology, and an overview of pharmacotherapy and treatment algorithms.
• The changing molecular target landscape between the market and the pipeline, and particular focal points of innovation in the pipeline.
• Comprehensive review of the pipeline for first-in-class therapies, analyzed on the basis of stage of development, molecule type and molecular target.
• Identification and assessment of first-in-class molecular targets, with a particular focus on early-stage programs for which clinical utility has yet to be evaluated, as well as literature reviews on novel molecular targets.
• Assessment of the licensing and co-development deal landscape for breast cancer therapies, and benchmarking of deals involving first-in-class versus non-first-in-class-products.

Reasons to buy

• Understand the current clinical and commercial landscape, including a comprehensive study of disease pathogenesis, diagnosis, prognosis and the available treatment options available at each stage of diagnosis.
• Visualize the composition of the breast cancer market in terms of dominant molecule types and targets, highlighting what the current unmet needs are and how they can be addressed. This knowledge allows a competitive understanding of the gaps in the current market.
• Analyze the breast cancer pipeline, stratified by stage of development, molecule type and molecular target.
• Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, first-in-class products have been assessed and ranked according to clinical potential. Promising early-stage targets have been further reviewed in greater detail.
• Identify commercial opportunities in the breast cancer deals landscape by analyzing trends in licensing and co-development deals, and producing a list of breast cancer therapies that are not yet involved in deals and may be potential investment opportunities.

About us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact

Mr. Nachiket

State Tower

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-621-2074

Website: http://www.marketresearchreports.biz/

E: sales@marketresearchreports.biz

Asia-Pacific Asthma Therapeutics Market Will Hit At $5.6 billion till year 2021

Latest industry research report on: Asia-Pacific Asthma Therapeutics Market : Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts

Asthma is a common chronic inflammatory disease of the airways, characterized by recurrent attacks of breathlessness and wheezing, which vary in frequency and severity from patient to patient. The exact causes of asthma are currently unknown, and may be the result of a combination of factors, although two major factors thought to be involved are environmental exposure and host factors, particularly genes.

Asthma treatment can be classed as either a long-term control medication, aimed at controlling persistent asthma, or a quick-relief medication, for the relief of exacerbations and acute symptoms. Long-term control medication includes Inhaled Corticosteroids (ICS), immunomodulators, leukotriene modifiers, cromolyn sodium, nedocromil and methylxanthines. In addition, Long-Acting Beta-Adrenoceptor Agonists (LABAs) can be used in combination with ICSs – but not as monotherapies – for moderate or severe persistent asthma. Currently, only one biologic – Xolair (omalizumab) – is approved as an add-on therapy for the treatment of allergic asthma in the Asia-Pacific region. Nevertheless, significant unmet need remains for the treatment of severe eosinophilic asthma.

Download Sample copy of this Report at : http://www.marketresearchreports.biz/sample/sample/686317

Scope

The current asthma market in the Asia-Pacific region contains novel products, including Xolair, a recombinant humanized monoclonal anti-IgE antibody; Seretide/Adoair, an ICS-LABA combination therapy; Relvar/Breo, an ICS-LABA combination therapy, and Spiriva, a LAMA.

• What are the competitive advantages of the existing novel drugs?

With over 274 active pipeline molecules, most of the late-stage investigational drug candidates are being evaluated, with improved dosing regimens and administration routes in comparison to currently marketed products.

• Which classes of novel drugs are most prominent within the pipeline?
• Is there strong potential for the pipeline to address unmet needs within the asthma market – specifically for severe eosinophilic asthma?

Analysis of clinical trials since 2006 has identified that the failure rates of asthma molecules were highest in Phase III (46%), with the overall attrition rate for asthma in development being 78%.

• How do failure rates vary by product stage of development, molecule type, and mechanism of action?
• How do other factors, such as average trial duration and trial size influence the costs and risks associated with product development?
• Over the 2014–2021 forecast period, the asthma therapeutics market in the Asia-

Pacific region is expected to increase in value at a Compound Annual Growth Rate (CAGR) of 7.2%, from $3.5 billion to over $5.6 billion.

• Which markets make the most significant contribution to the current market size?
• What are the epidemiology trends in these markets?
• Will new market entrants lead to substantial changes in annual therapy costs?
• How will different treatment usage patterns impact growth in the five assessed Asia-Pacific markets?

Rising asthma prevalence and uptake of newer biologics will lead to significant market growth over the forecast period, in spite of affordability concerns.

• Will affordability threaten the commercial success of existing drugs as well as newer biologics?
• Which of the assessed countries have affordability concerns?

Reasons to buy

This report will enable you to -

• Understand the clinical context of asthma by considering symptoms, etiology, pathophysiology, epidemiology, diagnosis, and treatment options.
• Identify the therapeutic strategies, products, and companies that dominate the current marketed products landscape and recognize gaps and areas of unmet need.
• Identify key pipeline trends in molecule type, administration route, mechanism of action, and novelty.
• Consider market opportunities and potential risks by examining trends in asthma clinical trial size, duration, and failure rate by stage of development, molecule type, and mechanism of action.
• Recognize the late-stage pipeline molecules that have demonstrated strong therapeutic potential in asthma by examining clinical trial data and multi-scenario product forecast projections.
• Compare treatment usage patterns, annual therapy costs, and market growth projections for China, India, Australia, South Korea and Japan.
• Discover trends in licensing and co-development deals concerning asthma products and identify the major strategic consolidations that have shaped the commercial landscape.

About us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact

Mr. Nachiket

State Tower

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-621-2074

Website: http://www.marketresearchreports.biz/

E: sales@marketresearchreports.biz

Asia-Pacific Alzheimers Therapeutics Market Will Reach At $5.1 billion in 2021

Latest industry research report on: Asia-Pacific Alzheimers Therapeutics Market | Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts

Alzheimers Disease (AD) is an irreversible, progressive neurodegenerative disease, characterized by cognitive impairment, memory loss and functional decline. Symptoms typically begin to first occur in patients in their mid-sixties, appearing in varying stages. The pathological features of AD comprise histopathological changes within the brain. Mild Cognitive Impairment (MCI) is a heterogeneous condition between normal cognition and dementia, whereby cognitive changes in mental abilities, such as memory or thinking, are affected. Almost all cases of AD begin with MCI, but it should be noted that not all patients with MCI go on to develop AD.

Although there is a high degree of failure and uncertainty within the R&D of AD drugs, the number of drugs in the pipeline is considerable, at 559. The majority of the pipeline products are novel, and there are only seven repositioned drugs and five generic drugs. This shows progression in terms of the different molecules being developed as therapeutic agents within the AD pipeline.

Download Sample copy of this Report at : http://www.marketresearchreports.biz/sample/sample/686320

Scope

The AD market has a lack of therapeutic options.

• Which classes of drug dominate the market?
• What newly approved therapies have entered the market?
• How do the leading marketed therapies compare clinically?
• How will the new therapies be positioned in the treatment of AD?
• How have selected late-stage pipeline therapies performed in clinical trials?

The pipeline contains a range of molecule types and molecular targets, including those that are well established in AD, and novel, first-in-class therapies.

• Which molecular targets appear most frequently in the pipeline?

AD clinical trials have an overall attrition rate of 94%.

• What are the failure rates for individual Phases of clinical development?
• How do AD clinical trial characteristics, including failure rate, duration, and size compare against respiratory and industry averages?

The AD market is forecast to rise from a value of $3 billion in 2014 to $5.1 billion in 2021, at a CAGR of 7.9% across the four Asia-Pacific markets assessed.

• How much of a role will disease prevalence and new product approvals play in market growth?
• Will generic competition have a significant impact on the market over the forecast period?

There have been 170 licensing deals and 104 co-development deals pertaining to AD products since 2006.

• Which territories show the most deal activity?
• What were the trends in deal completion by product stage of development?
• What were the conditions of the key licensing or co-development deals to take place in AD?

Reasons to buy

This report will allow you to -

• Understand the current clinical and commercial landscape through a comprehensive study of disease pathogenesis, diagnosis, prognosis, and the current treatment algorithm used in AD.
• Assess the safety and efficacy of current treatment options, with extensive product profiles on prominent marketed therapies, and a heatmap directly comparing safety and efficacy data.
• Analyze the AD pipeline and stratify by stage of development, molecule type, and molecular target. The most promising late-stage therapies are profiled and assessed in terms of clinical performance and competitiveness, alongside a single-product forecast.
• Predict growth in market size in four Asia-Pacific markets, with in-depth market forecasting from 2014 to 2021. The forecasts will provide an understanding of how epidemiology trends, new drug entries, and patent expirations will influence market value.
• Identify commercial opportunities in the AD deals landscape by analyzing trends in licensing and co-development deals, and by profiling the most significant deals that have occurred in this indication in recent years.

About us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact

Mr. Nachiket

State Tower

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-621-2074

Website: http://www.marketresearchreports.biz/

E: sales@marketresearchreports.biz